Bottom line
Is JCVSX a good fund? The bottom line
JCVSX is the Class R2 share class of Classic Value Fund, a managed large value mutual fund from John Hancock.
It charges 1.25% — about $125 a year on every $10,000 invested, more expensive than 81% of large value funds we track.
It returned +11.7% over one year, +10.3% a year over five years, +8.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $545 million in net assets and 37 holdings, its largest position is Baxter International Inc. (6.5%) and the top 10 make up 41.8% of the portfolio.
What to watch
- Expensive for its category (1.25%)
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What JCVSX invests in
To seek long-term growth of capital.
Under normal conditions, the fund invests at least 80% of its net assets in domestic equity securities. The manager seeks to identify companies that it believes are currently undervalued relative to the market, based on estimated future earnings and cash flow. These companies generally have market values at valuation ratios, such as price to book, below the market average defined by the S&P 500 Index. In choosing individual securities, the manager screens a dynamic universe of the 500 largest publicly traded U.S. companies. (As of December 31, 2025, those with market values above approximately $17 billion.) The manager uses fundamental research and proprietary modeling to rank these companies from the cheapest to the most expensive based on current share price relative to estimated long-term earnings power. Focusing on the cheapest-ranked companies, the manager constructs a portfolio…
From the fund's prospectus (filed Feb 25, 2026).
JCVSX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| JCVSX | +11.7% | +10.3% | +8.8% |
| Large Value median | +13.6% | +11.3% | +10.2% |
Source: Fund prospectus, as of Dec 31, 2025
What JCVSX costs
On a $10,000 investment, JCVSX's 1.25% expense ratio costs about $125 a year. The prospectus estimates $1,522 in total costs over 10 years (assuming 5% annual returns). The median large value fund charges 0.81%.
JCVSX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Baxter International Inc. BAX US | 6.53% |
| 2 | Humana Inc. HUM US | 5.13% |
| 3 | CVS Health Corporation CVS US | 4.53% |
| 4 | Fresenius Medical Care AG FMS US | 4.12% |
| 5 | Dollar General Corporation DG US | 3.75% |
| 6 | MetLife Inc. MET US | 3.75% |
| 7 | Corebridge Financial Inc. CRBG US | 3.59% |
| 8 | Global Payments Inc. GPN US | 3.51% |
| 9 | Wells Fargo and Company WFC US | 3.45% |
| 10 | Magna International Inc. MGA US | 3.40% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 41.8% of the fund. See all top 25 holdings and asset mix →